Collaborative Investing
During the 2019 Cross Pollinate Wine Retreat, several attendees discussed a local biotechnology business visited prior to the event. The attendees thought we should collectively invest in this business; leveraging the unique intellectual, human, relational and financial capital of the group. From this discussion, the partnership “Cross Pollinate Absci” was born in June 2020.
Cross Pollinate Capital partnerships have historically aligned interests of investors by charging an interest in profits with minimal fees or expenses.
Cross Pollinate’s initial partnership was dissolved in 2022, following the distribution of shares of Absci (NASDAQ: ABSI) following its successful initial public offering in July 2021. Additional partnerships investments were made into the software and bio-manufacturing business listed below.
Direct Venture Capital Investment
Create better biologics for patients, faster.
A generative AI drug creation company on a mission to create better biologics for patients, faster.
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.
Direct Growth / Lower Middle Market Buyout
Actionable Intel for the Emergency Services Community.
Intterra Inc is a leading provider of cloud-based software solutions tailored to meet the unique needs of public safety agencies. With a dedicated focus on improving data management and analysis, Intterra empowers fire departments, emergency response teams, and other public safety organizations to enhance their operational capabilities and ultimately save lives.
At the core of Intterra’s offerings is a suite of innovative software platforms designed to streamline critical processes and optimize resource allocation. Through intuitive interfaces and advanced functionalities, Intterra enables agencies to seamlessly collect, visualize, and analyze data in real-time, providing actionable insights to support informed decision-making.
With a commitment to innovation, reliability, and customer satisfaction, Intterra continues to set the standard for excellence in public safety software. By partnering with agencies across the globe, Intterra is dedicated to driving positive change and helping communities stay safe and resilient in the face of emergencies.
Direct Venture Capital Investment
Accelerate research with fast and reliable supply of Plasmid DNA
Novel Biotechnology is a leading provider of plasmid DNA solutions, dedicated to advancing scientific research and innovation. With a commitment to quality and efficiency, they offer custom plasmid DNA construction and manufacturing services at various scales, from small laboratory preparations to large-scale productions. Their state-of-the-art processes ensure high purity and integrity, meeting the diverse needs of researchers in fields such as gene therapy, vaccine development, and synthetic biology.
The company prioritizes rapid turnaround times without compromising quality, backed by robust quality control measures and sequencing capabilities.
In addition to their core services, Novel Biotechnology is committed to fostering innovation through collaborative partnerships and continuous improvement. They actively engage with the scientific community, providing resources and expertise to support research initiatives. By prioritizing customer satisfaction and scientific advancement, Novel Biotechnology aims to be the go-to partner for plasmid DNA solutions, facilitating breakthroughs that can transform healthcare and biotechnology.
